Dr. Czerwiec is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2675 S Bayshore Dr
Suite 1103S Clinical Development
Coconut Grove, FL 33133
Education & Training
- National Institutes of Health Clinical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 1994 - 1997
- University of Miami/Jackson Health SystemResidency, Internal Medicine, 1990 - 1994
- University of Miami Leonard M. Miller School of MedicineClass of 1990
Certifications & Licensure
- MD State Medical License 1994 - 2026
- VA State Medical License 1994 - 2024
Clinical Trials
- Tolvaptan Phase 3 Efficacy and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD) Start of enrollment: 2007 Jan 01
- Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD Start of enrollment: 2010 Oct 01
- Tolvaptan Extension Study in Participants With ADPKD Start of enrollment: 2010 May 26
- Join now to see all
Publications & Presentations
PubMed
- 17 citationsSafety and Efficacy of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Focal Segmental Glomerulosclerosis, Treatment-Resistant Minimal Change Disease, or Diabetic...Liron Walsh, John F. Reilly, Caitlin Cornwall, Gregory A Gaich, Debbie S. Gipson
Kidney International Reports. 2021-07-23 - 15 citationsThe NOCTURNE Randomized Trial Comparing 2 Tolvaptan Formulations.Ronald D. Perrone, Arlene B. Chapman, Dorothee Oberdhan, Frank S. Czerwiec, Olga Sergeyeva
Kidney International Reports. 2020-04-27 - 7 citationsA Randomized Trial of Modified-Release Versus Immediate-Release Tolvaptan in ADPKD.Ronald D. Perrone, Arlene B. Chapman, Dorothee Oberdhan, Frank S. Czerwiec, Olga Sergeyeva
Kidney International Reports. 2020-03-17
Press Mentions
- Sparrow Pharmaceuticals Announces Completion of Phase 2 Trial and FDA Orphan Drug Designation of Clofutriben for Endogenous Cushing’s SyndromeOctober 28th, 2024
- Chutes & Ladders—J&J CEO Gorsky to Step Aside, Handing World's Largest Pharma to COVID-19 Navigator DuatoAugust 20th, 2021
- Sparrow Pharmaceuticals Expands Executive Leadership with Appointment of Frank Czerwiec, MD as Chief Medical Officer and Jamie MacPherson, PharmD as Vice President of Regulatory Affairs and QualityAugust 17th, 2021
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: